Intra-Cellular Therapies
(NASDAQ) ITCI
This security has been delisted. This page is retained for historical reference.
ITCI News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowITCI Financials
Key Financial Metrics (TTM)
Gross Margin
92%
Operating Margin
-17%
Net Income Margin
-11%
Return on Equity
-9%
Return on Capital
-10%
Return on Assets
-5%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$623.89M
Operating Income
$116.72M
EBITDA
$116.72M
Operating Cash Flow
$73.18M
Capital Expenditure
$322.00K
Free Cash Flow
$73.50M
Cash & ST Invst.
$1.00B
Total Debt
$16.98M
Intra-Cellular Therapies Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$199.22M
+51.5%
Gross Profit
$178.82M
+48.0%
Gross Margin
89.76%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
860
N/A
Net Income
$16.89M
+40.9%
EBITDA
$29.09M
+14.3%
Quarterly Fundamentals
Net Cash
$984.09M
+104.6%
Accounts Receivable
$166.50M
+46.0%
Inventory
$26.28M
+125.7%
Long Term Debt
$12.75M
-4.3%
Short Term Debt
$4.23M
+17.2%
Return on Assets
-5.46%
N/A
Return on Invested Capital
-10.05%
N/A
Free Cash Flow
$12.65M
-513.5%
Operating Cash Flow
$13.08M
-534.5%